GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Cyclically Adjusted FCF per Share

Galectin Therapeutics (Galectin Therapeutics) Cyclically Adjusted FCF per Share : $-0.56 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Galectin Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.195. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.56 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Galectin Therapeutics was 13.10% per year. The lowest was -3.30% per year. And the median was 9.00% per year.

As of today (2024-05-26), Galectin Therapeutics's current stock price is $3.05. Galectin Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-0.56. Galectin Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Galectin Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Galectin Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Cyclically Adjusted FCF per Share Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.49 -0.50 -0.52 -0.54 -0.55

Galectin Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.55 -0.56 -0.55 -0.56

Competitive Comparison of Galectin Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Galectin Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galectin Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.195/131.7762*131.7762
=-0.195

Current CPI (Mar. 2024) = 131.7762.

Galectin Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.110 100.560 -0.144
201409 -0.149 100.428 -0.196
201412 -0.140 99.070 -0.186
201503 -0.187 99.621 -0.247
201506 -0.126 100.684 -0.165
201509 -0.214 100.392 -0.281
201512 -0.178 99.792 -0.235
201603 -0.121 100.470 -0.159
201606 -0.159 101.688 -0.206
201609 -0.118 101.861 -0.153
201612 -0.164 101.863 -0.212
201703 -0.114 102.862 -0.146
201706 -0.144 103.349 -0.184
201709 -0.089 104.136 -0.113
201712 -0.102 104.011 -0.129
201803 -0.094 105.290 -0.118
201806 -0.081 106.317 -0.100
201809 -0.039 106.507 -0.048
201812 -0.049 105.998 -0.061
201903 -0.073 107.251 -0.090
201906 -0.046 108.070 -0.056
201909 -0.026 108.329 -0.032
201912 -0.089 108.420 -0.108
202003 -0.077 108.902 -0.093
202006 -0.046 108.767 -0.056
202009 -0.144 109.815 -0.173
202012 -0.095 109.897 -0.114
202103 -0.112 111.754 -0.132
202106 -0.103 114.631 -0.118
202109 -0.084 115.734 -0.096
202112 -0.117 117.630 -0.131
202203 -0.135 121.301 -0.147
202206 -0.125 125.017 -0.132
202209 -0.141 125.227 -0.148
202212 -0.122 125.222 -0.128
202303 -0.181 127.348 -0.187
202306 -0.165 128.729 -0.169
202309 -0.128 129.860 -0.130
202312 -0.076 129.419 -0.077
202403 -0.195 131.776 -0.195

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Galectin Therapeutics  (NAS:GALT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Galectin Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (Galectin Therapeutics) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025

Galectin Therapeutics (Galectin Therapeutics) Headlines

From GuruFocus